降糖减重神药一年狂揽超2500亿元

Core Viewpoint - The competition for the "king of drugs" title in the GLP-1 market is intensifying between Novo Nordisk and Eli Lilly, with Eli Lilly's GLP-1 drug tirzepatide significantly contributing to its revenue growth in 2025 [1][2]. Group 1: Eli Lilly's Financial Performance - Eli Lilly reported total revenue of $65.179 billion for the year 2025, a 44% increase year-over-year at constant exchange rates [1][2]. - The key driver of this growth was the GLP-1 drug tirzepatide, which generated $36.5 billion in revenue (approximately 253.4 billion RMB) [1][3]. - In Q4 2025, Eli Lilly's revenue reached $19.29 billion, a 43% year-over-year increase, with net profit soaring to $20.64 billion, up 95% [2]. Group 2: Market Dynamics and Competition - The GLP-1 market is currently dominated by Eli Lilly and Novo Nordisk, with combined revenues approaching $50 billion in 2024 [6]. - Eli Lilly's tirzepatide is positioned to capture both diabetes and obesity markets, with Zepbound's sales growth of 175% outpacing Mounjaro's growth in diabetes [1][2]. - Novo Nordisk's oral GLP-1 drug Wegovy has received FDA approval, intensifying competition in the market [7]. Group 3: Pricing and Future Outlook - Eli Lilly faces increasing pricing pressure, with both companies agreeing to lower prices for their GLP-1 drugs starting November 2025 [9]. - The global GLP-1 market is expected to see significant growth, with sales projected to exceed $17 billion by 2031, reflecting a compound annual growth rate of 15.6% from 2021 to 2031 [10]. - The competition is shifting from a "blue ocean" market to a more competitive landscape, with a focus on efficacy, convenience, pricing accessibility, and expanded indications [10].